title: Oral heparin: status review.
abstract: Unfractionated heparin and low molecular weight heparin are the most commonly used antithrombotic and thromboprophylactic agents in hospital practice. Extended out-of-hospital treatment is inconvenient in that these agents must be administered parenterally. Current research is directed at development of a safe and effective oral antithrombotic agent as an alternative for the effective, yet difficult to use vitamin K antagonists. A novel drug delivery technology that facilitates transport of drugs across the gastrointestinal epithelium has been harnessed to develop an oral dosage form of unfractionated heparin. Combining unfractionated heparin with the carrier molecule, sodium N-(8 [2-hydroxybenzoyl]amino) caprylate, or SNAC has markedly increased the gastrointestinal absorption of this drug. Preclinical and clinical studies to-date suggests that oral heparin-SNAC can confer a clinical efficacious effect; further confirmation is sought in planned clinical trials.
authors: Emisphere Technologies Inc, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA. earbit@emisphere.com
authors: Ehud
authors: E
authors: Arbit
authors: Michael
authors: M
authors: Goldberg
authors: Isabel
authors: I
authors: Gomez-Orellana
authors: Shingai
authors: S
authors: Majuru